Pfizer (NYSE: PFE) is truly facing a challenge of unprecedented magnitude at the moment. While patent issues are something pharmaceutical companies have struggled with from time to time throughout history, Pfizer is being walloped …
Tara Clarke: Pfizer Inc. (NYSE:PFE) will soon feel the pressure from the wave of lawsuits being filed claiming that Pfizer’s blockbuster drug Lipitor – the world’s best-selling drug of all time – causes type-2 diabetes in women. With a market ...
09/14 Pfizer and Astellas Announce Positive Top-Line Results from Phase 3 PROSPER T.. 09/14 Pfizer and Astellas Announce Positive Top-Line Results from Phase 3 PROSPER T.. 09/14 BRIEF-Astellas Pharma and Pfizer say positive …
Pfizer (PFE) said it filed suit in the U.S. District Court for the ... In the absence of such coverage, providers - who depend on reimbursement from insurers - are reluctant to stock biosimilars, even to service Medicare and Medicaid patients …
The stock should discover initial support at its 200-day moving average (MA) of $32.28 and subsequent support at its 50-day MA of $31.25. SmarTrend is tracking the current trend status for Pfizer Inc and will alert subscribers who have PFE
With or without mid-term elections, the last quarter of 2014 and January of next year could be a bonanza for stock investors ... Pfizer Inc. (NYSE: PFE) trades at a low 14 times earnings and is one of the top pharmaceutical stocks at …
Jefferies analyst Jeffrey Holford raised his price target on Buy-rated Pfizer (NYSE: PFE) to $45.00 (from $42.00) and added the stock to the Jefferies "Franchise Picks" list. Holford commented, "We expect PFE shares to significantly …
Meanwhile, Dow component Pfizer Inc. (NYSE:PFE) helped boost the blue-chip index higher after ... at 17,832.03; the …
Buy stuff we need, like, you know, pills. Cause people are always going to need pills. Here's how that's working out with Pfizer, which just bet the farm on acquiring Wyeth. See Also: Pfizer/Wyeth Verdict: Thumbs Down Get the latest Pfizer …
Pfizer Inc. (NYSE: PFE) shareholders have experienced the short-term euphoria of seeing their stock rally a massive 10 percent from August to September. The stock failed to eclipse key “triple threat” resistance (created by a horizontal line ...